| Budget Amount *help |
¥204,230,000 (Direct Cost: ¥157,100,000、Indirect Cost: ¥47,130,000)
Fiscal Year 2021: ¥37,830,000 (Direct Cost: ¥29,100,000、Indirect Cost: ¥8,730,000)
Fiscal Year 2020: ¥36,400,000 (Direct Cost: ¥28,000,000、Indirect Cost: ¥8,400,000)
Fiscal Year 2019: ¥38,610,000 (Direct Cost: ¥29,700,000、Indirect Cost: ¥8,910,000)
Fiscal Year 2018: ¥46,280,000 (Direct Cost: ¥35,600,000、Indirect Cost: ¥10,680,000)
Fiscal Year 2017: ¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
|
|---|
| Outline of Final Research Achievements |
We induced kidney organoids via nephron progenitors from iPS cells derived from a patient with congenital nephrotic syndrome and recapitulated the initial disease states, including impaired formation of glomerular filtration slits. We also developed an induction method for the ureteric bud, the second renal progenitor, and applied it to autosomal dominant polycystic kidney disease to reproduce cyst formation. Furthermore, we successfully induced stromal progenitors and combined them with two other progenitors derived from mouse ES cells to reconstitute the higher-order kidney structures, all of which were derived from pluripotent stem cells.
|
